These prescription medications mimic a natural hormone your body produces to control hunger and metabolism
Having followed obesity medication development for years, I genuinely believe Retatrutide will reshape how we think about weight management once it reaches widespread availability
The weight loss studies on the weekly injection show an average of 15% weight loss
The response from many of those employers has been swift: Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity treatment for employers with fewer than 100 employees at the start of 2026 Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan both dropped weight-loss GLP-1 coverage in 2026 HCA Healthcare one of the countrys largest hospital systems notified employees that its GLP-1 coverage was ending after usage surged 90% in a single year, directing workers instead toward manufacturer cash-pay programs Several other employers have stopped short of elimination but have tightened requirements dramatically restricting coverage only to patients with a formal diabetes diagnosis and removing access for patients using GLP-1s for weight management alone. Why Are Employers Cutting This Coverage Now
Berberine and chromium, which play an important role in the AI formula for blood sugar regulation, are also present in GLP-1 ProBoost
Oral semaglutide (Rybelsus) already exists for diabetes, with daily doses of 3, 7, or 14 mg compared to the weekly injectable range of 0.25-2.4 mg
